STADA Arzneimittel AG — Earnings Release 2001

Aug 22, 2001

News Details

Ad-hoc | 22 August 2001 08:53

STADA Arzneimittel AG english

Ad hoc announcement processed and transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– STADA Arzneimittel AG in the first six months of 2001: Successful course continues STADA Arzneimittel AG has successfully continued its growth course in the first six months of 2001. Notwithstanding last year’s record level, sales in the reporting period rose by +14% to DM 526.4 million. Organic growth (excluding the effects of acquisitions) totaled +13%. This consistent and broadly-based international growth, in which all company segments and most distributors play a part, will enable STADA by the end of fiscal year 2001 to clearly exceed the sales threshold of 1 billion DM. STADA’s earnings growth has also been gratifying in the first six months of 2001. The generated EBITDA of DM 73.3 million equals an Increase of +30% compared to last year’s result, which was adjusted due to one-time expenses for last year’s capital increase. In addition, for the year as a whole the executive board expects EBITDA growth to exceed organic growth. In so doing, STADA will dearly achieve Its income goal of significant double-digit EBITDA growth in 2001 as well. Pre-tax profits (results from ordinary business activities) rose in the first six months of 2001 to DM 51.7 million (+33% compared to last year). Net income for the year after taxes showed a nominal increase of +9% compared to last year’s relevant number due to a one-time payment in the 2nd quarter of 2001 of DM 4.2 million in tax arrears fur the years 1995 to 1998. However, adjusted for this one-time expense, net income for the year rose In the first six months of 2001 by +27%. Earnings per share according to DVFA rose by +28% in the first six months of 2001 to DM 1.43. STADA reconfirmed its peak position in product development in the first six months of 2001 by Introducing group-wide a total of 94 new products, among them in turn several products launches exactly timed to patent expiration. The development cooperation for blogenerics started In January 2001 was launched according to plan; biogeneric product launches are expected starting in 2005 as planned. The 1:1 conversion of STADA preferred shares into registered STADA shares with restricted transferabillty that was approved at the June 19, 2001 annual shareholders’ meeting has since been entered into the Commercial Register. Deutsche Börse AG will implement the change technically in the fall. The complete information presented at today’s press conference, i.e. semi- annual report, a detailed press release, the charts and other information regarding STADA Arzneimittel AG are published in German and English on the Internet at http://www.stada.de. For further information, please contact: STADA Arzneimittel AG / Corporate Communications / 61118 Bad Vilbel Tel.: +49(0) 6101 603-113 / Fax: +49(0) 6101 603-506 / E-mail: communication@stada.de Or visit us on the Internet at http://www.stada.de Executive Board: Hartmut Retzlaff (Chairman) / Dipl.-Kfm. Wolftang Jeblonski / Dipl.-Ing. Peter Niemann Chairman of the Supervisory Board: Dr. Eckhard Brüggemann end of ad hoc announcement (c) DGAP 22.08.2001 ——————————————————————————– WKN: 725180; Index: MDAX Listed: Amtlicher Handel in Frankfurt und Düsseldorf; Freiverkehr in Berlin, Bremen, Hamburg, München und Stuttgart 220853 Aug 01